U.S. Physical Therapy, Inc. (USPH) Company Overview

What does U.S. Physical Therapy do?

U.S. Physical Therapy, Inc. is a Houston-based healthcare-services company listed under the ticker USPH on the New York Stock Exchange and NYSE Texas. Its core business is operating and managing outpatient physical therapy clinics, while a smaller but faster-growing industrial injury prevention, or IIP, segment places clinicians and safety specialists at employer locations. The company therefore sits at the intersection of rehabilitation, occupational health, and decentralized healthcare delivery rather than pharmaceutical manufacturing or hospital ownership.

Which patients and customers does the company serve?

Physical therapy clinics treat orthopedic and sports injuries, pre- and post-operative patients, neurological conditions, and injured workers. Revenue is generally tied to completed visits and contracted reimbursement rates from commercial insurers, Medicare, Medicaid, workers’ compensation programs, and patients. IIP is different: employers contract for onsite injury prevention, rehabilitation, ergonomic assessment, functional testing, and performance optimization. The Q1 2026 Form 10-Q confirms these two reportable segments and the company’s dual exchange listing.

How does U.S. Physical Therapy make money?

USPH combines a visit-based clinical model with a partnership-based ownership structure. In many acquisitions, the company buys a controlling stake while local therapist-founders retain meaningful equity and continue operating the practice. That arrangement is central to the model: USPH supplies capital, billing, compliance, payor contracting, recruiting support, technology, and purchasing scale, while local partners preserve clinical relationships and entrepreneurial incentives. The company’s official partnership description emphasizes that local brands remain in place and owners continue running the business.

Which segment contributes most?

Physical therapy is the dominant revenue source. In Q1 2026 it generated $167.7 million, while IIP generated $30.6 million. That mix means clinic density, therapist productivity, reimbursement, and acquisition integration still explain most of USPH’s value. IIP nevertheless matters disproportionately because its Q1 2026 margin was 20.4%, above physical therapy’s 15.8%, and its revenue grew faster.

Which payors and revenue drivers matter most?

The clinic segment is not a simple consumer-pay business. Most cash comes through negotiated reimbursement systems, so volume and price are partly controlled by insurers and government programs. In FY2025, commercial and managed-care programs represented 48.5% of net patient revenue, Medicare and Medicaid 35.8%, workers’ compensation 10.2%, and other payors 5.5%. This mix spreads exposure, but it also makes contract terms, authorization rules, documentation, and collections as important as patient demand.

What creates revenue growth?

For analysis, mature-clinic growth is the cleanest organic signal because it excludes most acquisition effects. The central trade-off is that acquisitions can accelerate revenue, but sustainable value depends on maintaining therapist productivity and margins after the acquired practice joins the platform.

What did U.S. Physical Therapy’s latest quarter show?

The Q1 2026 earnings release showed healthy top-line growth but mixed margin and GAAP earnings signals. Total net revenue increased 7.9% to $198.3 million. Physical therapy revenue rose 7.2%, supported by 6.9% visit growth and a modest improvement in net rate per visit. IIP was the faster-growing segment, with revenue up 11.8% and positive same-store growth.

Why did GAAP earnings look weaker than operations?

Fair-value remeasurement of contingent consideration reduced comparability with the prior year. Redeemable noncontrolling interests also affect per-share earnings because local partners retain put rights. Researchers should reconcile GAAP results with management’s adjusted measures rather than treating either view as complete.

What strategic turning points shaped USPH?

USPH evolved through operating-model extensions rather than one transformative launch: outpatient therapy, a local-partner structure, larger acquisitions, IIP, and hospital affiliations. Each step broadened the addressable market while preserving decentralized clinic leadership.

1. 1990
   The company was founded around outpatient physical therapy, establishing the visit-based clinical model that remains the main revenue source.
2. 2005 onward
   USPH institutionalized acquisition-led expansion and built a repeatable process for sourcing and integrating local practices.
3. 2017
   The initial IIP entry added employer-paid services, reducing sole dependence on insurance reimbursement.
4. 2024
   The Metro transaction added a large platform and demonstrated willingness to use more complex partnership and management structures.
5. 2025
   USPH ended the year with 780 clinics, showing that active additions and closures are both part of portfolio management.
6. 2026
   Hospital affiliations, a larger credit facility, and continued acquisitions broadened the platform and extended its national reach.

What does the July 2026 acquisition signal?

The July 2026 announcement follows the established template: USPH acquired a majority interest in a multi-clinic practice while existing owners retained equity. The structure confirms that local ownership remains the preferred tool for aligning sellers with post-close performance.

Who competes with USPH, and what is its moat?

Outpatient rehabilitation is competitive and fragmented. USPH faces national and regional chains, hospital-owned clinics, physician-affiliated practices, and independent therapist-owned businesses. Its SEC-filed Q1 2026 investor presentation describes a highly fragmented market without a dominant national operator. That structure creates both rivalry and a long consolidation runway.

What resources are difficult to replicate?

The moat is organizational, not technological. Its durability depends on remaining a preferred buyer, retaining clinicians, and coordinating local practices without damaging the referral relationships that made them valuable.

How strong are USPH’s margins, cash flow, and balance sheet?

FY2025 provides the clearest annual baseline. Revenue rose 16.3% to $781.0 million, with physical therapy contributing $666.6 million and IIP $114.4 million. Gross profit reached $149.7 million, equal to 19.2% of revenue, and adjusted EBITDA was $95.0 million. The company produced $75.1 million of operating cash flow and spent $14.1 million on fixed assets, implying approximately $61.0 million of free cash flow before acquisitions, partner-interest transactions, and financing activities.

How should free cash flow be interpreted?

This is a relatively asset-light clinical model: clinics require leased space and equipment, but acquisitions absorb more capital than routine property spending. At March 31, 2026, cash was $28.4 million and borrowings were $203.9 million. USPH subsequently established a $450 million facility consisting of a $175 million term loan and $275 million revolver. Liquidity supports growth, but higher leverage increases sensitivity to interest expense and acquisition execution.

How does USPH allocate capital?

Capital allocation centers on acquisitions and new clinics, partner-interest purchases, dividends, and debt management. The company declared a $0.46 quarterly dividend in May 2026, but acquisitions remain the main strategic use of capital. Redeemable interests and earn-outs make the full economic cost broader than closing cash.

Why do partner put rights matter?

Local partners may have contractual rights that require USPH to purchase their retained interests under specified conditions. Those obligations are remeasured and can create volatility in equity and per-share earnings even when clinic operations are stable. For valuation, the analyst should treat partner interests, contingent consideration, and future buyouts as real claims on enterprise cash flow, not as accounting footnotes. This is one reason adjusted EBITDA can be useful operationally but insufficient on its own.

Who owns USPH stock, and how is it governed?

USPH has a single-class, equal-vote structure, so there is no founder-controlled dual-class arrangement. The latest 2026 proxy statement shows a predominantly institutional shareholder base. BlackRock was the largest disclosed holder at 14.4%, followed by Kayne Anderson Rudnick at 8.0%, Morgan Stanley at 6.6%, and Copeland Capital Management at 5.1%. Directors and executive officers as a group held 2.4% as of March 19, 2026.

What leadership issues should researchers note?

Christopher Reading serves as chairman and chief executive officer and beneficially owned 0.9% in the proxy. The company’s leadership page identifies Jason Curtis as interim chief financial officer from April 24, 2026, following Carey Hendrickson’s resignation. That transition matters because USPH is expanding debt capacity and executing complex transactions at the same time. The board’s committee structure and governance documents are available on the official corporate governance page.

Which KPIs, opportunities, and risks matter most?

USPH’s operating dashboard should combine volume, reimbursement, labor productivity, segment margin, and acquisition quality. Revenue alone can look strong while mature-clinic growth weakens or cost per visit rises. In Q1 2026, mature-clinic revenue increased, but adjusted labor and total operating cost per visit also rose. That pattern explains why physical therapy margin declined despite higher visits and reimbursement.

Where could the business expand?

The largest opportunity is continued consolidation, especially when sellers value retained ownership and local autonomy. Hospital affiliations can add scale, while IIP deepens employer relationships and reduces reimbursement dependence. Demographics and the shift toward lower-cost outpatient care support demand; therapist availability determines whether that demand becomes profitable visits.

Why does USPH’s business model matter for valuation?

A DCF for USPH should not begin with a generic healthcare revenue-growth assumption. The model needs separate drivers for mature-clinic revenue, acquired-clinic contributions, IIP growth, reimbursement, visits, and cost per visit. Physical therapy gross margin is especially important because small changes in labor productivity can materially affect consolidated cash flow. IIP deserves its own assumptions because its customer model and recent margin trajectory differ from the clinic segment.

Which assumptions deserve the most sensitivity analysis?

• Mature-clinic growth: test whether organic revenue can remain positive after acquisition effects fade.
• Physical therapy margin: vary reimbursement and cost per visit independently rather than applying a single margin trend.
• Acquisition pace and returns: distinguish revenue purchased from value created, and include financing plus future partner-interest purchases.
• IIP durability: model same-store growth, contract retention, and segment margin separately.
• Terminal assumptions: reflect reimbursement regulation, labor intensity, and limited national market concentration rather than assuming software-like economics.

Comparable-company analysis also requires care. USPH has healthcare-services demand characteristics, an acquisition platform, decentralized joint economics, and accounting volatility from retained partner interests. Enterprise-value multiples should therefore be reconciled to the actual cash claims beneath adjusted EBITDA.

The key takeaway from U.S. Physical Therapy analysis

U.S. Physical Therapy has built national scale in a locally fragmented market. Its central resource is a partnership model that acquires control while keeping clinician-founders economically engaged, supporting deal sourcing, referral continuity, local execution, and centralized administrative scale.

The same structure creates the research tension. Growth and cash generation are attractive, but reimbursement, labor costs, leverage, and retained partner rights can dilute acquisition economics. Key indicators are mature-clinic revenue, visits per clinic, rate and cost per visit, IIP margin, acquisition returns, and debt relative to adjusted EBITDA.